US 11324822
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11324822 (Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer) held by Syndax Pharmaceuticals, Inc. expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Syndax Pharmaceuticals, Inc.
- Grant date
- Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/4406